Zepbound vs Retatrutide: Side-Effect Profile Head-to-Head

Why No Direct Comparison Exists Yet

No randomized controlled trial has placed Zepbound and retatrutide in the same study population. All side-effect comparisons are cross-trial, meaning they rely on data generated under different protocols, patient populations, inclusion criteria, and dose-escalation schedules. This limits the strength of any safety conclusion drawn between the two agents.

Zepbound's safety profile comes primarily from the SURMOUNT-1 trial (N=2,539), a 72-week Phase 3 RCT published in the New England Journal of Medicine in 2022 [1]. Retatrutide's safety data derive from the Phase 2 dose-finding study by Jastreboff et al. (N=338), published in NEJM in 2023 [2]. The Phase 2 trial was shorter (48 weeks), enrolled fewer participants, and tested multiple dose arms ranging from 1 mg to 12 mg. These structural differences affect discontinuation rates, adverse-event capture, and the precision of safety estimates.

Cross-trial comparison remains the only available method until Eli Lilly's Phase 3 program for retatrutide reports topline data. Clinicians should interpret the figures below as hypothesis-generating, not definitive.

Mechanism Differences That Drive Side Effects

Zepbound activates two receptors: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and the glucagon receptor. That third receptor matters for tolerability.

Glucagon receptor agonism increases hepatic glucose output, stimulates lipolysis, and raises resting energy expenditure [3]. It also accelerates bile acid cycling and may amplify nausea through central and peripheral pathways distinct from GLP-1-mediated emesis. The glucagon component is the primary pharmacological differentiator between these two drugs, and it likely explains retatrutide's higher GI adverse-event signal at equivalent weight-loss efficacy timepoints.

GIP co-agonism, shared by both drugs, appears to partially buffer GLP-1-mediated nausea. Preclinical evidence from Samms et al. (2022) suggests GIP signaling in the area postrema attenuates emetic responses triggered by GLP-1 [4]. This buffering effect is present in both agents but may be partially overwhelmed in retatrutide by the additive glucagon signal.

Gastrointestinal Side Effects: The Dominant Concern

GI adverse events are the most common reason patients discontinue incretin-based therapies. Both drugs follow a predictable pattern: nausea peaks during dose escalation and attenuates at maintenance.

Zepbound (SURMOUNT-1 to 15 mg arm):

• Nausea: 31% (vs. 9.5% placebo)
• Diarrhea: 23%
• Vomiting: 12%
• Constipation: 11%
• GI-related discontinuation: 4.3%

Retatrutide (Phase 2 to 12 mg arm):

• Nausea: 45%
• Diarrhea: 30%
• Vomiting: 18%
• Constipation: 14%
• GI-related discontinuation: approximately 6%

These numbers are not directly comparable due to trial-design differences. The retatrutide Phase 2 study used a more aggressive escalation schedule in some cohorts, and the smaller sample size produces wider confidence intervals [2]. Still, the directional signal is consistent: retatrutide produces more GI distress, particularly nausea.

The temporal pattern also differs. In SURMOUNT-1, nausea with tirzepatide 15 mg peaked between weeks 4 and 8, then declined below 5% incidence by week 20 [1]. Retatrutide nausea in the 12 mg arm remained above 10% at week 24, though it trended downward by study end [2]. Whether this reflects the glucagon component's sustained GI effect or the compressed trial timeline remains unclear.

Hepatobiliary and Pancreatic Safety Signals

Glucagon receptor activation increases hepatic lipid oxidation. This is therapeutically desirable for MASLD but raises theoretical concerns about cholelithiasis. In the retatrutide Phase 2 trial, 2 participants (12 mg arm) developed cholelithiasis requiring cholecystectomy [2]. In SURMOUNT-1, gallbladder-related events occurred in 0.6% of the tirzepatide group vs. 0.2% placebo [1].

Rapid weight loss itself increases gallstone risk independent of drug mechanism. A 2024 meta-analysis in Lancet Gastroenterology found that weight loss exceeding 1.5 kg/week approximately doubles cholelithiasis incidence across all interventions, pharmacologic and surgical [5]. Since retatrutide produces faster early weight loss, disentangling drug-specific from weight-loss-speed effects requires further study.

Pancreatitis signals have been minimal in both programs. SURMOUNT-1 reported 0 confirmed cases of acute pancreatitis in the tirzepatide arms [1]. The retatrutide Phase 2 study reported 1 case in the 8 mg arm, adjudicated as possibly related [2]. Lipase elevations above 3x ULN occurred in 1.2% of retatrutide participants vs. 0.8% in Zepbound across studies. These rates do not exceed background population incidence.

Cardiovascular and Heart-Rate Effects

Both GLP-1 and glucagon receptor agonists increase resting heart rate by 2 to 4 bpm on average. In SURMOUNT-1, tirzepatide 15 mg increased heart rate by a mean of 2.6 bpm at week 72 [1]. Retatrutide 12 mg increased heart rate by 3.1 bpm at week 48 [2].

The clinical significance of these small increases remains debated. The SELECT trial demonstrated cardiovascular benefit with semaglutide 2.4 mg despite a similar heart-rate increase (N=17,604 to 20% MACE reduction) [6]. No cardiovascular outcomes trial has been completed for either tirzepatide or retatrutide in obesity populations, though SURPASS-CVOT for tirzepatide in type 2 diabetes is expected to read out in 2026.

Blood pressure reductions favor both agents. Tirzepatide 15 mg reduced systolic BP by 7.2 mmHg in SURMOUNT-1 [1]. Retatrutide 12 mg reduced systolic BP by 9.5 mmHg, likely reflecting the glucagon-driven increase in energy expenditure and more aggressive fat mass reduction [2].

Injection-Site Reactions and Hypersensitivity

Both drugs are administered as once-weekly subcutaneous injections. Injection-site reactions (ISRs) are mild and infrequent in both programs.

Zepbound ISR rate: 3.2% (SURMOUNT-1) [1]. Retatrutide ISR rate: 4.7% (Phase 2) [2]. No anaphylaxis or serious hypersensitivity events have been reported in either trial. The slightly higher ISR rate with retatrutide may reflect formulation differences in the investigational product rather than pharmacological effects.

Tirzepatide carries a labeled warning for serious hypersensitivity reactions including angioedema, based on postmarketing reports from its diabetes indication (Mounjaro), though confirmed cases are extremely rare (estimated <1 per 100,000 patients) [7].

Thyroid C-Cell and Medullary Thyroid Carcinoma Concerns

All GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies. This applies to Zepbound. Retatrutide, if approved, would carry an identical warning.

No confirmed cases of medullary thyroid carcinoma (MTC) attributable to tirzepatide have been reported in clinical trials or postmarketing surveillance through 2025 [7]. Calcitonin monitoring is not recommended by the American Thyroid Association for patients on GLP-1 agonists unless there is a personal or family history of MTC or MEN2 [8].

Retatrutide's glucagon receptor component does not add theoretical thyroid risk. Glucagon receptors are not expressed on human thyroid C-cells at clinically meaningful density.

Metabolic Side Effects: Hypoglycemia and Muscle Loss

Hypoglycemia is uncommon with both agents when used without concomitant insulin or sulfonylureas. In SURMOUNT-1, clinically significant hypoglycemia (glucose <54 mg/dL) occurred in 0.1% of the tirzepatide group [1]. No severe hypoglycemia events were reported in the retatrutide Phase 2 trial [2].

Lean mass loss is a concern with all high-efficacy weight-loss drugs. In SURMOUNT-1, approximately 33% of total weight lost with tirzepatide 15 mg was lean mass, measured by DEXA substudy [1]. Retatrutide Phase 2 did not include a body-composition substudy, so lean mass data are unavailable. The glucagon receptor's protein-catabolic effects raise theoretical concern that retatrutide may produce proportionally greater lean mass loss, but this remains speculative until Phase 3 DEXA data are available.

Dr. Ania Jastreboff, lead investigator of both the tirzepatide and retatrutide obesity programs at Yale, stated in a 2023 interview: "The triple-agonist approach gives us more metabolic levers to pull, but each additional receptor carries its own safety questions that only larger, longer trials can answer" [9].

Tolerability Management: Dose Escalation Strategies

Slow dose escalation is the primary strategy for managing GI side effects with both drugs. Zepbound's FDA-approved escalation schedule starts at 2.5 mg weekly for 4 weeks, then 5 mg for 4 weeks, with subsequent 2.5 mg increases every 4 weeks to a maximum of 15 mg [7].

Retatrutide's Phase 2 protocol tested multiple escalation speeds. The most tolerable arm used 4-week intervals between dose increases [2]. Phase 3 trials (TRIUMPH program) are expected to use optimized escalation based on Phase 2 tolerability data.

The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends extending escalation intervals by 2 to 4 weeks if GI symptoms do not resolve at a given dose [10]. This approach reduced discontinuation rates by approximately 40% in post-hoc analyses of GLP-1 agonist trials.

Who Might Tolerate One Drug Better Than the Other

Patients with pre-existing gastroparesis or severe GERD may find retatrutide's higher nausea rates less acceptable. Patients with MASLD or significant hepatic steatosis might benefit from retatrutide's glucagon-mediated hepatic lipid oxidation despite the GI cost.

The American Gastroenterological Association's 2024 guidance on GLP-1 agonists and GI motility recommends avoiding incretin-based therapies in patients with documented gastroparesis with gastric retention on scintigraphy [11]. For patients with functional dyspepsia without objective motility disorder, GLP-1 agonists may be trialed with close monitoring.

Age also matters. Patients over 65 had higher GI adverse-event rates with tirzepatide in SURMOUNT-1 subgroup analyses (nausea 38% vs. 29% in those under 65) [1]. Retatrutide Phase 2 enrolled few participants over 65, so age-stratified safety data are limited.

The Regulatory Gap: What Approval Status Means for Safety Data

Zepbound's FDA approval means it has undergone full NDA review including integrated safety analyses across multiple Phase 3 trials (SURMOUNT-1 through SURMOUNT-4), postmarketing surveillance, and REMS evaluation [7]. As of May 2026, approximately 9 million tirzepatide prescriptions have been dispensed in the U.S. across obesity and diabetes indications, generating substantial real-world safety data.

Retatrutide remains investigational. Its safety database consists of approximately 700 patients exposed across Phase 1 and Phase 2 studies. Phase 3 trials (TRIUMPH-1 through TRIUMPH-4) are enrolling, with primary completion dates projected for late 2026 to 2027 [12]. Until Phase 3 data, retatrutide's true side-effect frequency, rare event rates, and long-term safety remain uncertain.

The FDA's guidance on benefit-risk assessment requires at minimum 1,500 patients exposed for 6 months and 400 for 12 months before approval [13]. Retatrutide has not yet met these thresholds for its obesity indication.

Bottom Line for Clinicians

Zepbound offers a known, well-characterized safety profile with 72-week Phase 3 data and extensive postmarketing experience. Retatrutide shows a directionally higher GI adverse-event burden in Phase 2, likely driven by glucagon receptor agonism, but may deliver superior weight loss. The 24.2% body-weight reduction at 48 weeks in the retatrutide 12 mg arm [2] compared to 20.9% at 72 weeks with tirzepatide 15 mg [1] suggests a steeper efficacy curve, though the safety cost of that curve is not yet fully quantified. Prescribing decisions between these agents will require Phase 3 completion, and for many patients, direct tolerability experience through managed dose escalation.